By Josh White
Date: Thursday 11 Dec 2025
(Sharecast News) - Eli Lilly reported the first successful phase three results for retatrutide, its experimental once-weekly 'triple agonist' drug, showing unprecedented weight loss alongside major improvements in knee osteoarthritis pain.
| Currency | US Dollars |
| Share Price | $ 1,080.36 |
| Change Today | $ 5.68 |
| % Change | 0.53 % |
| 52 Week High | $1,109.94 |
| 52 Week Low | $625.65 |
| Volume | 12,317 |
| Shares Issued | 948.17m |
| Market Cap | $1,024,365m |
| Beta | 0.70 |
| RiskGrade | 179 |
| Strong Buy | 12 |
| Buy | 12 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

You are here: research